Susceptibility Evaluation of Aspergillus fumigatus to Silver Nanoparticles Compared with Voriconazole

Authors
Bahareh Bashardoust 1
Shahla Roudbar Mohammadi 1
Shahla Roudbar Mohammadi 1
Maryam Roudbary 2
Fateme Nikoomanesh 1
1 Department of Medical Mycology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran
2 Department of Parasitology and Mycology, School of Medical Sciences, Iran University of Medical Sciences, Tehran, IR Iran
Abstract
Background: This study was performed to determine antifungal activity of silver nanoparticles (nano-Ag) compared to voriconazole on clinical and standard strains of Aspergillus fumigatus.
Materials and Methods: Inhibitory potency of nano-Ag was determined using microtiter broth dilution method. Susceptibility tests were performed against A. fumigatus isolated from BAL (bronchoalveolar lavage) of patients who suffered from respiratory problems and compared with the strain (ATCC: 204305) by broth dilution antifungal susceptibility test of filamentous fungi approved by the Clinical and Laboratory Standards Institute M38-A. In addition, cytotoxicity effect of silver nanoparticles was studied on epithelial cell line by MTT assay.
Results: From 60 BAL samples the following strains were isolated; A. flavus (n=21), A. niger (n=3), and A. fumigatus (n=1). The minimum inhibitory concentration (MIC90) values of nano-Ag were 0.25 and 0.5 μg.mL-1 for standard strain and clinical isolates respectively. The Minimum Fungicidal Concentration (MFC) values of nano-Ag were 0.5 and 1 μg.mL-1for standard strain and clinical isolates respectively. MIC90 values of voriconazole were 0.125 and 0.25 μg.mL-1 for standard strain and clinical isolate respectively. The MFC values of voriconazole were 0.25 and 0 μg.mL-1 for standard strain and clinical isolates respectively. Silver nanoparticles exhibited low cytotoxicity in 0.25 μg.mL-1 concentration.
Conclusion: Our results showed high antifungal activity of silver nanoparticles against Aspergillus isolates. Furthermore, the availability of a wide form of nano-Ag structures can be considered as novel agents to decrease fungal burden in medical application.

Keywords

  1. Rementeria A, López-Molina N, Ludwig A, Vivanco AB, Bikandi J, Pontón J, et al. Genes and molecules involved in Aspergillus fumigatus virulence. Rev Iberoam Micol. 2005; 22(1):1-23.

  2. Latgé J-P. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. 1999; 12(2):310-50.

  3. Chrdle A, Mustakim S, Bright-Thomas R, Baxter C, Felton T, Denning D. Aspergillus bronchitis in non-immunocompromised patients–case series, response to treatment and criteria for diagnosis. Ann NY Acad Sci. 2012; 1272:73-85.

  4. Denning DW. Aspergillosis: diagnosis and treatment. Int J Antimicrobial Agents. 1996; 6(3):161-8.

  5. Espinel-Ingroff A, Fothergill A, Peter J, Rinaldi M, Walsh T. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol. 2002; 40(9):3204-8

  6. Jain J, Arora S, Rajwade JM, Omray P, Khandelwal S, Paknikar KM. Silver nanoparticles in therapeutics: development of an antimicrobial gel formulation for topical use. Mol Pharm. 2009; 6(5):1388-401.

  7. Panáček A, Kolář M, Večeřová R, Prucek R, Soukupová J, Kryštof V, et al. Antifungal activity of silver nanoparticles against Candida spp. Biomaterials. 2009; 30(31):6333.

  8. Panáček A, Kvitek L, Prucek R, Kolar M, Vecerova R, Pizurova N, et al. Silver colloid nanoparticles: synthesis, characterization, and their antibacterial activity. J Phys Chem B. 2006; 110(33):16248-53.

  9. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Ramírez JT, et al. The bactericidal effect of silver nanoparticles. Nanotechnology. 2005; 16(10):2346.

  10. Pulit J, Banach M, Szczygłowska R, Bryk M. Nanosilver against fungi. Silver nanoparticles as an effective biocidal factor. Acta biochim Pol. 2013; 60(4):795-8.

  11. Panda KK, Achary VMM, Krishnaveni R, Padhi BK, Sarangi SN, Sahu SN, et al. In vitro biosynthesis and genotoxicity bioassay of silver nanoparticles using plants. Toxicol In Vitro. 2011; 25(5):1097-105.

  12. Van Der Linden J, Arendrup M, Verweij P, editors. Prospective international surveillance of azole resistance in Aspergillus fumigatus (SCARE-Network). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011.

  13. Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints. Drug Resist Updat. 2009; 12(6):141-7.

  14. Denning DW, Bowyer P. Editorial Commentary: Voriconazole Resistance in Aspergillus fumigatus: Should We Be Concerned? Clin Infect Dis. 2013; 57(4):521-3.

  15. Denning DW, Venkateswarlu K, Oakley KL, Anderson M, Manning N, Stevens DA, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 1997; 41(6):1364-8.

  16. Beernaert L, Pasmans F, Van Waeyenberghe L, Dorrestein G, Verstappen F, Vercammen F, et al. Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole. Antimicrob Agents Chemother. 2009; 53(5):2199-201.